AIF1L

Across TCGA pan-cancer cohorts, AIF1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AIF1L data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AIF1L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AIF1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where AIF1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.984	0.748	.001	112	view →
LUAD	OS	Tertile	All	0.907	0.443	<.001	39	view →
HNSC	DFS	Tertile	All	1.000	0.307	.016	35	view →
PDAC	OS	Quartile	II,III,IV	0.413	0.637	.009	6	view →
GBM	OS	Median	All	0.559	0.271	.003	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AIF1L–CCRCC (OS)

Open the CCRCC breakdown →